Drug developer Summit Therapeutics is taking part in the JMP Securities Duchenne muscular dystrophy (DMD) forum on December 14.
Drug developer (NASDAQ:SMMT: ) is taking part in the JMP Securities Duchenne muscular dystrophy (DMD) forum on December 14.
The day will focus on key themes and trends in DMD and feature discussions with publicly traded and privately held biopharmaceutical companies developing therapies.
Summit is running a Utrophin modulation programme, which is a potential disease modifying approach that aims to treat all patients with this muscle-wasting disease.
JMP Securities is an investment banking firm, which provides equity research, institutional brokerage services to growth companies and their investors.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE